Physician profile
Savitha Gowda
NPI 1609927276
$2,134.85
in general payments reported to CMS, 2019-2025
26 companies · $775 in 2025
The $775 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $34.98 · 2021: $135 · 2022: $307 · 2023: $402 · 2024: $314 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.96 | 2022-2025 | |
| Pfizer INC. | $355.25 | 2019-2025 | |
| Novo Nordisk INC | $156.35 | 2023-2025 | Wegovy, Ozempic |
| Abbott Laboratories | $155.68 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals Lp | $113.19 | 2023-2025 | Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $100.37 | 2023-2025 | |
| Shield Therapeutics INC | $81.00 | 2023-2025 | Accrufer |
| Sunovion Pharmaceuticals INC. | $80.92 | 2019-2020 | |
| Lilly USA, LLC | $80.07 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $78.33 | 2021-2022 | |
| Lundbeck LLC | $47.45 | 2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $44.90 | 2025 | |
| Medtronic, INC. | $39.19 | 2024-2025 | Minimed 780g, Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.88 | 2023-2024 | Xifaxan |
| Ars Pharmaceuticals Operations, INC. | $29.32 | 2025 | Neffy |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $28.65 | 2023 | Gemtesa |
| Exact Sciences Corporation | $26.38 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $25.62 | 2024 | Veozah |
| Biogen, INC. | $22.02 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.69 | 2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $20.54 | 2025 | Lagevrio |
| Scpharmaceuticals INC. | $20.41 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $18.95 | 2021 | |
| Edwards Lifesciences Corporation | $16.95 | 2025 | |
| Amgen INC. | $14.27 | 2023 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Savitha Gowda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.